Is 23andMe’s DNA Empire Crumbling?

Three years ago, 23andMe, the DNA-testing company, was a sensation. Its share price soared, even surpassing Apple’s, as millions eager to uncover their ancestry and genetic makeup eagerly sent in saliva samples. But today, that success story seems like a distant memory. 23andMe is battling for survival, its share price plummeted, and it narrowly avoided being delisted from the stock market. What happened?

From DNA Gold Rush to Troubled Waters

It wasn’t always this way. Celebrities like Snoop Dogg, Oprah Winfrey, Eva Longoria, and even Warren Buffet promoted 23andMe. People were captivated by the company’s ability to reveal surprising familial connections and potential health risks. In a matter of years, 23andMe became a household name.

But the company lacked a sustainable business model. Once people had their DNA reports, there wasn’t much incentive to keep coming back. This, coupled with delayed profitability from its ambitious plans to leverage anonymized DNA data for drug research, has fueled 23andMe’s struggles.